share_log

港股异动 | 和铂医药-B(02142)盘中跌超6% 预计上半年溢利同比下滑约48.3%至65.5%

Hong Kong stock abnormality | Hebo Pharmaceuticals-B (02142) fell more than 6% during the day, and it is expected that the first half profit will decrease by about 48.3%-65.5% year-on-year.

Zhitong Finance ·  Jul 19 02:38

Hepalink Pharmaceutical-B (02142) fell over 6% during trading, and as of the time of publication, fell 4.83% to HKD 1.38 with a turnover of 1.9591 million Hong Kong dollars.

According to the Zhitong Finance App, Hepalink Pharmaceutical-B (02142) fell over 6% during trading, and as of the time of publication, fell 4.83% to HKD 1.38 with a turnover of 1.9591 million Hong Kong dollars.

On the news front, Hepalink Pharmaceutical issued a profit warning, expecting a profit of approximately US$1 million to US$1.5 million for the six months ending June 30, 2024. This is a decrease of approximately 48.3% to 65.5% compared to the same period last year, when the profit was around US$ 2.9 million. The announcement stated that the decrease in expected profits is mainly due to changes in the income structure, especially the increased proportion of service fees from the services business compared to the first half of last year's revenue. However, compared to the large proportion of authorized income in last year's revenue, the profit margin of this type of income is relatively low. Therefore, the overall profit for the first half of this year has decreased.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment